Form 4: TriSalus Exec Granted 50K RSUs, 100K Stock Options

TriSalus Life Sciences' Chief of Clinical Operations, Jodi Devlin, was granted 50,000 restricted stock units and 100,000 employee stock options.

Summary

• Jodi Devlin, Chief of Clinical Operations at TriSalus Life Sciences, Inc. (TLSI), acquired 50,000 shares of common stock through a Restricted Stock Unit (RSU) Award.
• The RSU Award vests in four equal annual installments, commencing on November 24, 2025, contingent on continued employment.
• Devlin also acquired 100,000 employee stock options with an exercise price of $5.55 per share.
• One-fourth of the shares subject to the option will vest on the one-year anniversary of the vesting commencement date of November 24, 2025, with 1/36th of the remaining shares vesting monthly thereafter, subject to continued employment.
• Following these transactions, Devlin beneficially owns 100,571 shares of common stock directly and 463,750 derivative securities (employee stock options) directly.

Sentiment

Score: 7

Explanation: The grant of significant equity awards to a key executive is generally positive for aligning management incentives with shareholder interests and promoting long-term retention, indicating confidence in the executive's role and future company performance.

Positives

• The grant of 50,000 Restricted Stock Units (RSUs) and 100,000 employee stock options aligns the executive's long-term interests with those of shareholders.
• Equity awards serve as a strong incentive for executive retention and performance, as vesting is contingent on continued employment.

Negatives

• The equity awards do not provide immediate liquidity or cash benefits to the executive.
• Vesting schedules mean the full benefit of the awards is realized over several years and is subject to the executive's continued employment.

Risks

• The value of the granted RSUs and stock options is subject to the future market price fluctuations of TriSalus Life Sciences' common stock.
• Forfeiture of unvested awards could occur if the executive's employment ceases before the vesting dates.

Future Outlook

The equity grants are structured to incentivize long-term commitment and performance from a key executive, aligning their financial success with the company's future growth and stock performance.

Industry Context

The grant of equity compensation, including Restricted Stock Units and stock options, is a standard practice in the life sciences and biotechnology industry to attract, retain, and motivate key executives, linking their compensation directly to company performance and shareholder value creation.

Comparison to Industry Standards

• It is not possible to assess the specific compensation package against global benchmarks or comparable companies solely based on this Form 4 filing, as it lacks details on the executive's total compensation, performance targets, or peer group comparisons.

Stakeholder Impact

• Shareholders: Potential positive impact through enhanced executive alignment with long-term company performance and value creation.
• Employees (Jodi Devlin): Direct financial benefit tied to the company's stock performance and continued employment.

Next Steps

• The granted Restricted Stock Units will begin vesting in four equal annual installments starting November 24, 2025.
• The employee stock options will begin vesting one year after November 24, 2025, with subsequent monthly vesting.

Key Dates

Keywords

TriSalus Life Sciences, TLSI, Form 4, insider transaction, stock options, restricted stock units, RSU, equity grant, executive compensation, Jodi Devlin